Loading Events

« All Events

  • This event has passed.

Accelerating Clinical Development from First-in-Human to Proof-of-Concept

Tuesday 21st February 2017 @ 8:00 am - 5:00 pm


This seminar will describe how Quotient Clinical’s unique Enabled-First-in-Human® programs significantly reduce the time and cost required to transition to Proof of Concept.  The integration of real-time GMP manufacture and clinical testing minimises CMC investments and simplifies supply chains.  By enhancing the design and speed of early phase clinical programs, the pressure on R&D budgets is reduced and critical decisions are made sooner.

Presentation 1: First-in-Human to Proof-of-Concept – there is a better way!

Alyson Connor, Executive Director Exploratory Clinical Pharmacology

A current perspective on the conduct of First-in-Human (FIH) programs in the UK will be shared, highlighting the benefits of Quotient’s innovative approach.  Case studies will illustrate successes across a range of molecule classes and indications.

Presentation 2: Adaptive CMC strategies for First in Human programs

Nikki Whitfield, Vice President, Pharmaceutical Sciences

Insights into novel approaches for the development of fit-for-purpose FIH drug products to allow rapid entry into clinic will be described.  Proven strategies for a time- and cost-efficient transition, within the FIH programme, to a product suitable for downstream development will be presented.

To register your place, please email Ciaran Flanagan.

This event is also taking place in London on Friday 3 March. To go to the event page, please click here.


Tuesday 21st February 2017
8:00 am - 5:00 pm
Event Category:


Cambridge Building
Babraham Research Campus
Cambridge, CB22 3AT
+ Google Map